← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 31, 2026

Ardent Health, Inc. (ARDT)

Healthcare • NYSE

$10.96

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

37.0/100

WEAK BUSINESS

Ardent Health, Inc. (ARDT) scores 37/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ARDT quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

Margin of Safety unavailable — insufficient data for the owner-earnings DCF.

BRINA GAP ↗

Is the market underestimating or overestimating what this business is capable of going forward?

-7.1%

Market Overestimates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ARDT valuation analysis · → View full ARDT Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (4.6%)

Debt-to-Equity (Solvency Risk):AVERAGE (0.72x)

Operating Margin (Operational Efficiency):POOR (3.2%)

Return on Capital (Capital Efficiency):POOR (7.9%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Ardent Health, Inc. (ARDT) stock report — Zyberno Score 37/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, Ardent Health, Inc. (ARDT) shows a Brina Gap of -7.1%, which weakens the case: based on the company's ROIC (7.9%) and reinvestment rate (-91.8%), the business can fundamentally grow at -7.2% — but the current enterprise value implies the market expects -0.1%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:10.96

Market Cap:$1.55B

Valuation Multiples (4)

P/E Ratio:

19.93x

📊 Click to view full ARDT P/E analysis →

P/B Ratio:0.89x

P/S Ratio:0.24x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$1.93B

Ev Ebitda Ratio:5.21x

Price Action & Momentum (3)

12-1 Momentum:

+3.3% (18th pctile)

📈 Click to view full ARDT Momentum analysis →

Momentum Percentile:18 / 100

% of 52-Week High:70.8%

B. Profitability Assessment

Return Metrics (7)

ROE:

4.6%

📊 Click to view full ARDT ROE analysis →

ROA:1.5%

Roic:

7.9%

📊 Click to view full ARDT ROIC analysis →

Reinvestment Rate:-91.8%

Fundamental Growth Rate (g):-7.2%

Market-Implied Growth Rate:-0.1%

Brina Gap:

-7.1%

☷ Click to view full ARDT Brina Gap analysis →

Margin Analysis (3)

Operating Margin Ttm:3.2%

Net Margin Ttm:1.2%

Ebitda Margin:5.8%

TTM Performance (2)

Operating Margin Ttm:3.2%

Net Margin Ttm:1.2%

Yield Metrics (2)

Earnings Yield:$5.02

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):6.0%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-14.9%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-9.3%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.10x

Quick Ratio:1.99x

Cash Ratio:0.74x

Leverage Analysis (3)

Debt To Equity Ttm:0.72x

Debt-to-Equity Ratio:0.72x

Debt To Ebitda:2.97x

Coverage Ratios (2)

Interest Coverage Ratio:5.61x

Times Interest Earned:5.61

Capital Structure (4)

Working Capital:1,078,553,000.00

Cash And Cash Equivalents:724,476,000.00

Long Term Debt:$1.07B

Net Debt:$377.31M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $6.41B

Linear Growth: 6.0%

📊 Click to view full ARDT Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00

Operating income TTM: $207.96M

Linear Growth: -9.3%

📊 Click to view full ARDT Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: $78.23M

Linear Growth: -14.9%

📊 Click to view full ARDT Net Income analysis & methodology →

Income Before Tax:$207.96M

Ebitda Ttm:370,450,000.00

Operating Expenses (5)

Operating Expenses:6,197,978,000.00

R And D Expense:0.00

Sga Expense:183,100,000.00

Income Tax Expense:$39.32M

Interest Expense:51,077,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:11.3%

Ebitda Margin:5.8%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.28B

Current Assets:$2.05B

Ppe Net:887,984,000.00

Goodwill:879,262,000.00

Intangible Assets:$87.68M

Liability Structure (4)

Total Liabilities:3,538,674,000.00

Current Liabilities:976,323,000.00

Long Term Debt:$1.07B

Short Term Debt:$28.57M

Equity & Capital (3)

Equity:$1.75B

Retained Earnings:$558.36M

Common Stock:750,000,000.00

Working Capital Items (3)

Accounts Receivable:695,950,000.00

Inventory:116,022,000.00

Accounts Payable:429,769,000.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

$435.08M$0.00

Investment Activities (1)

Investing Cash Flow:-$27.90M

Financing Activities (3)

Financing Cash Flow:-$11.79M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$3.64M

Non-Cash Items (1)

Depreciation Amortization Ttm:162,488,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.54

Eps diluted TTM: $0.55

Linear Growth: -18.1%

📊 Click to view full ARDT EPS analysis & methodology →

Earnings Per Share Ttm:$0.55

Revenue & Cash Per Share (2)

Sales Per Share Ttm:45.21

Operating Cash Flow Per Share:$3.32

Book Value & Capital (2)

Book Value Per Share:$12.32

Cash Per Share:5.11

Dividend Policy (1)

Dividend Payout Ratio:0.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.22x

Working Capital Turnover Ttm:5.94x

Receivables Management (2)

Receivables Turnover Ttm:9.20x

Days Sales Outstanding Ttm:39.65

Inventory Management (2)

Inventory Turnover Ttm:55.21x

Days Inventory Outstanding Ttm:6.61

Payables & Cash Cycle (2)

Days Payable Outstanding:24.49

Cash Conversion Cycle:21.78

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00

Quality Score:80.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-91.8%

Fundamental Growth Rate (g):-7.2%

Market-Implied Growth Rate:-0.1%

Brina Gap:

-7.1%

☷ Click to view full ARDT Brina Gap analysis →

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):6.0%

Net Income Growth Rate (Linear):-14.9%

Operating Income Growth Rate (Linear):-9.3%

Other Growth Rates (1)

Book Value Growth Rate (Linear):19.9%

C. Company Profile & Context

Corporate Information (6)

Symbol:ARDT

Company Name:Ardent Health, Inc.

Sector:Healthcare

Industry:Services-General Medical & Surgical Hospitals, NEC

Exchange:NYSE

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:141.69M

Shares Outstanding Basic:141.69M

Shares Outstanding Diluted:143.05M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-31 19:15:32 UTC

Data Timestamp:2026-08-31T19:15:32.051909